https://www.pharmaceutical-technology.com/data-insights/caba-201-cabaletta-bio-idiopathic-inflammatory-myopathy-iim-likelihood-of-approval/
CABA-201 is under clinical development by Cabaletta Bio and currently in Phase II for Idiopathic Inflammatory Myopathy (IIM).
inflammatory myopathycababioidiopathiciim